Article
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC.
Thoracic cancer - 1 Nov 2022
Tyler Logan C, Le Anh T, Chen Nan, Nijmeh Hala, Bao Liming, Wilson Timothy R, Chen David, Simmons Brian, Turner Kristen M, Perusse Dean, Kasibhatla Shailaja, Christiansen Jason, Dudek Arkadiusz Z, Doebele Robert C
Abstract excerpt
BACKGROUND: ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling. While multiple TKIs have been designed to target ROS1 KD mutations, less is known about bypass signaling in TKI-resistant ROS1+ lung cancers. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.